Clinical trial
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous…
NCT04464434 · UMC Utrecht, Other · Recruiting
Key facts
| NCT number | NCT04464434 |
|---|---|
| Title | Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis |
| Official title | Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial |
| Acronym | UPSIDE |
| Lead sponsor | UMC Utrecht, Other |
| Collaborators | ZonMw: The Netherlands Organisation for Health Research and Development Boehringer Ingelheim Industry Miltenyi Biotec, Inc. |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy |
| Intervention type | Procedure |
| Interventions | Upfront autologous HSCT |
| Enrollment | 50 |
| Start date | Sep 17, 2020 |
| Primary completion | Oct 1, 2027 |
| Completion | Oct 1, 2030 |
| First posted | Jul 9, 2020 |
| Last update posted | Dec 6, 2024 |
| Countries | Italy, Netherlands, Sweden, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: